Zymeworks Inc. 2023 Form 10-K Summary
Business context and reporting period
Zymeworks is a clinical-stage biotechnology company developing multifunctional antibody therapeutics, primarily for oncology. Its lead candidate is zanidatamab, a HER2-targeted bispecific antibody partnered with Jazz and BeiGene. The company also develops zanidatamab zovodotin, a HER2-targeted antibody-drug conjugate, and preclinical ADC and multispecific programs.
The filing covers the fiscal year ended December 31, 2023. The supplied metadata refers to “2023 Q4,” but this is an annual Form 10-K rather than a quarterly filing.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Collaboration revenue | $76.0 million | $412.5 million | Down $336.5 million, or 82% |
| Research and development expense | $143.6 million | $208.6 million | Down 31% |
| General and administrative expense | $70.4 million | $73.4 million | Down 4% |
| Operating loss | $138.1 million | Operating income of $130.5 million | Significant adverse change |
| Other income, net | $18.8 million | $4.7 million | Up $14.1 million |
| Net loss | $118.7 million | Net income of $124.3 million | Significant adverse change |
| Basic loss per share | $1.72 | Basic earnings per share of $1.91 | Significant adverse change |
| Net cash used in operating activities | $118.3 million | Cash provided of $144.1 million | Significant adverse change |
Revenue was primarily collaboration-related and included $91.6 million of Jazz development-support and drug-supply revenue, reduced by a $20.1 million credit issued to Jazz under the amended collaboration arrangement, plus $4.5 million of research-support and other payments. The prior year included $375.0 million of Jazz upfront fees.
Approximate reported operating margin was negative 182% in 2023, compared with positive 32% in 2022; approximate net margin was negative 156% in 2023, compared with positive 30% in 2022. These ratios reflect collaboration revenue rather than product sales and are not representative of commercial product margins.
At December 31, 2023, cash, cash equivalents and marketable securities totaled $456.3 million, consisting of $157.6 million of cash and cash equivalents and $298.7 million of marketable securities. Total assets were $580.9 million, total liabilities were $116.1 million, and stockholders’ equity was $464.8 million. The filing does not report conventional funded debt; lease liabilities totaled $26.8 million, including $26.6 million of operating lease liabilities.
Financing activities generated $81.8 million of cash, including $26.2 million of net proceeds from the ATM offering and $49.9 million of net proceeds from a December 2023 private placement of pre-funded warrants. Investing activities used $207.3 million, primarily for net purchases of marketable securities. Management expects existing liquidity, together with certain anticipated collaboration milestones, to fund operations and capital requirements for at least twelve months from the filing date, but states that substantial additional funding will be required for longer-term plans.
Material changes versus the prior comparable period
- Revenue fell sharply because 2022 included $375.0 million of Jazz upfront payments; 2023 revenue was primarily development support and drug supply.
- Research and development expense declined as responsibility for the zanidatamab program transferred to Jazz in May 2023. Zanidatamab-related expense fell to $44.8 million from $117.4 million.
- Spending increased on preclinical programs ZW171 and ZW191, to $10.7 million and $11.7 million, respectively, and zanidatamab zovodotin expense increased to $8.0 million.
- Zymeworks completed a $26.2 million net ATM equity issuance and a $49.9 million net private placement of pre-funded warrants, increasing potential dilution.
- BeiGene’s zanidatamab zovodotin license was terminated in September 2023. The separate zanidatamab collaboration remained in place, with royalties amended to up to 19.5%, potentially increasing to 20% after a specified cumulative royalty reduction cap.
- LEO elected to terminate its research and license agreement; termination became effective January 25, 2024. No milestone or royalty revenue had been received under that agreement.
- Headcount declined following the transfer of certain zanidatamab personnel to Jazz. Zymeworks had 277 employees at year-end, including 272 full-time employees.
Guidance, outlook, commentary and unusual items
- Jazz initiated a rolling U.S. BLA submission for zanidatamab in second-line biliary tract cancer and expected to complete it in the first half of 2024. Jazz is targeting a U.S. launch in 2025 or earlier, subject to approval.
- BeiGene expects to submit a Chinese BLA for zanidatamab in biliary tract cancer in the second half of 2024.
- Jazz is targeting late-2024 top-line data from the Phase 3 HERIZON-GEA-01 trial. Enrollment was increased from 714 to 918 patients to improve statistical power for the overall-survival endpoint, while maintaining the previously targeted readout timing.
- Zymeworks expects to submit IND or foreign-equivalent applications for ZW191 and ZW171 in 2024, for ZW220 and ZW251 in 2025, and for a fifth development program in 2026. The filing also states that ZW251’s anticipated filing was expected in the second half of 2025.
- Zanidatamab zovodotin remains positioned for a potential Phase 2 combination study with pembrolizumab at a recommended dose of 2.5 mg/kg every three weeks, but initiation has been deprioritized pending greater clarity on the clinical landscape and potential collaborations.
- Zymeworks remains eligible for up to $525.0 million of Jazz regulatory milestones, $862.5 million of Jazz commercial milestones and royalties of 10% to 20% on future Jazz sales. Under the BeiGene zanidatamab agreement, it remains eligible for up to $172.0 million of additional development and commercial milestones and royalties of up to 19.5%, potentially increasing to 20%.
- Clinical data for zanidatamab showed promising activity, but the candidates remain investigational. No product has received regulatory approval or generated product-sales revenue.
- The company recorded a $20.1 million revenue reduction related to the Jazz amendment. The transaction was identified as a critical audit matter because of the judgment required to evaluate the contract modification.
- Key risks include clinical-trial failure or delay, regulatory rejection, adverse events, reliance on Jazz and other partners, third-party manufacturing and CRO dependence, competition and biosimilars, intellectual-property challenges, cybersecurity incidents, and the need for additional capital.
Most important facts for investors to verify
- Confirm the timing and outcome of the U.S. zanidatamab BLA submission, any FDA action, and the potential 2025 launch.
- Monitor the late-2024 HERIZON-GEA-01 readout and the effect of increased enrollment on timing and statistical interpretation.
- Assess whether anticipated Jazz and BeiGene milestones are achieved; these amounts are contingent and are not guaranteed revenue.
- Reconcile the $456.3 million liquidity position with quarterly cash burn and determine the duration of the cash runway without future milestones or financing.
- Evaluate dilution from the 5,086,521 pre-funded warrants, outstanding options, restricted stock units and any future equity financing.
- Track development prioritization and collaboration status for zanidatamab zovodotin and the ZW171, ZW191, ZW220 and ZW251 programs.
- Review the full financial statements and notes for deferred collaboration revenue of $36.6 million, contingent consideration of $1.9 million, lease obligations of $26.8 million and tax-loss carryforwards.
- Consider the dependence on Jazz for zanidatamab development and commercialization, including Jazz’s contractual right to terminate the collaboration with notice.